Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Inflammation as Treatment Target for Status Epilepticus

Author(s): Konrad Rejdak*, Agata Pikulicka, Małgorzata Piekarska, Katarzyna Pacek and Kamila Płachta

Volume 21, Issue 3, 2023

Published on: 26 December, 2022

Page: [708 - 714] Pages: 7

DOI: 10.2174/1570159X21666221117152249

Price: $65

Abstract

Background: Status epilepticus (SE) is a serious neurological disease that manifests as prolonged seizures that last more than 5 minutes and between such episodes, patients do not regain consciousness. It can result in cognitive defects, brain damage, or even death. It is commonly known that one of the causes can be an inflammatory process, but here we will focus on inflammation as a result of new onset refractory status epilepticus and, related to this, new promising forms of SE treatment. Particular emphasis has been focused on new-onset refractory status epilepticus (NORSE).

Methods: Based on public research databases, drugs with anti-inflammatory activity – commonly used in different spheres of medicine – have been reviewed as potentially treating status epilepticus.

Results: There is seizable clinical research suggesting that drugs that decrease inflammatory processes might be effective in terminating status epilepticus.

Conclusion: There is growing evidence showing that adding anti-inflammatory drugs to basic antiepileptic treatment enhances the efficiency of the therapeutic process, with special potential in NORSE cases.

Keywords: Status epilepticus, new-onset refractory status epilepticus (NORSE), secondary inflammation, antiepileptic, antiinflammatory activity, seizures.

« Previous Next »
Graphical Abstract

[1]
Trinka, E.; Brigo, F.; Shorvon, S. Recent advances in status epilepticus. Curr. Opin. Neurol., 2016, 29(2), 189-198.
[http://dx.doi.org/10.1097/WCO.0000000000000307] [PMID: 26886360]
[2]
Vezzani, A.; Dingledine, R.; Rossetti, A.O. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev. Neurother., 2015, 15(9), 1081-1092.
[http://dx.doi.org/10.1586/14737175.2015.1079130] [PMID: 26312647]
[3]
DeLorenzo, R.J.; Pellock, J.M.; Towne, A.R.; Boggs, J.G. Epidemiology of status epilepticus. J. Clin. Neurophysiol., 1995, 12(4), 316-325.
[http://dx.doi.org/10.1097/00004691-199512040-00003] [PMID: 7560020]
[4]
Hesdorffer, D.C.; Logroscino, G.; Cascino, G.; Annegers, J.F.; Hauser, W.A. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology, 1998, 50(3), 735-741.
[http://dx.doi.org/10.1212/WNL.50.3.735] [PMID: 9521266]
[5]
Knake, S.; Rosenow, F.; Vescovi, M.; Oertel, W.H.; Mueller, H.H.; Wirbatz, A.; Katsarou, N.; Hamer, H.M. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia, 2001, 42(6), 714-718.
[http://dx.doi.org/10.1046/j.1528-1157.2001.01101.x] [PMID: 11422324]
[6]
Chin, R.F.M.; Neville, B.G.R.; Peckham, C.; Bedford, H.; Wade, A.; Scott, R.C. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet, 2006, 368(9531), 222-229.
[http://dx.doi.org/10.1016/S0140-6736(06)69043-0] [PMID: 16844492]
[7]
Jallon, P.; Coeytaux, A.; Galobardes, B.; Morabia, A. Incidence and case-fatality rate of status epilepticus in the Canton of Geneva. Lancet, 1999, 353(9163), 1496.
[http://dx.doi.org/10.1016/S0140-6736(99)00583-8] [PMID: 10232322]
[8]
DeLorenzo, R.J.; Hauser, W.A.; Towne, A.R.; Boggs, J.G.; Pellock, J.M.; Penberthy, L.; Garnett, L.; Fortner, C.A.; Ko, D. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology, 1996, 46(4), 1029-1035.
[http://dx.doi.org/10.1212/WNL.46.4.1029] [PMID: 8780085]
[9]
Mayer, S.A.; Claassen, J.; Lokin, J.; Mendelsohn, F.; Dennis, L.J.; Fitzsimmons, B.F. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch. Neurol., 2002, 59(2), 205-210.
[http://dx.doi.org/10.1001/archneur.59.2.205] [PMID: 11843690]
[10]
Janigro, D.; Iffland, P.H., II; Marchi, N.; Granata, T. A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia, 2013, 54(Suppl. 6), 30-32.
[http://dx.doi.org/10.1111/epi.12271] [PMID: 24001067]
[11]
Wang, M.; Chen, Y. Inflammation: A network in the pathogenesis of status epilepticus. Front. Mol. Neurosci., 2018, 11, 341.
[http://dx.doi.org/10.3389/fnmol.2018.00341] [PMID: 30344475]
[12]
Wang, Y.; Liu, X.; Wang, Y.; Chen, J.; Han, T.; Su, L.; Zang, K. Attenuation of pentylenetrazole-induced acute status epilepticus in rats by adenosine involves inhibition of the mammalian target of rapamycin pathway. Neuroreport, 2017, 28(15), 1016-1021.
[http://dx.doi.org/10.1097/WNR.0000000000000878] [PMID: 28902712]
[13]
Citraro, R.; Leo, A.; Constanti, A.; Russo, E.; De Sarro, G. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol. Res., 2016, 107, 333-343.
[http://dx.doi.org/10.1016/j.phrs.2016.03.039] [PMID: 27049136]
[14]
Terrone, G.; Balosso, S.; Pauletti, A.; Ravizza, T.; Vezzani, A. Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology, 2020, 167107742
[http://dx.doi.org/10.1016/j.neuropharm.2019.107742] [PMID: 31421074]
[15]
Gorter, J.A.; van Vliet, E.A.; Aronica, E. Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis. Epilepsy Behav., 2015, 49, 13-16.
[http://dx.doi.org/10.1016/j.yebeh.2015.04.047] [PMID: 25958228]
[16]
Rempe, R.G.; Hartz, A.M.S.; Soldner, E.L.B.; Sokola, B.S.; Alluri, S.R.; Abner, E.L.; Kryscio, R.J.; Pekcec, A.; Schlichtiger, J.; Bauer, B. Matrix metalloproteinase-mediated blood-brain barrier dysfunction in epilepsy. J. Neurosci., 2018, 38(18), 4301-4315.
[http://dx.doi.org/10.1523/JNEUROSCI.2751-17.2018] [PMID: 29632167]
[17]
Kasselman, L.J.; Ransohoff, R.M.; Cai, N.; Croll, S.D.; Cai, N.; Zhang, Q.; Martin, F.J.; Wei, T.; Kintner, J.; Murphy, A.J.; Yancopoulos, G.D.; Wiegand, S.J. Vascular endothelial growth factor (VEGF)-mediated inflammation precedes angiogenesis in adult rat brain. Exp. Neurol., 2004, 187, 388-402.
[http://dx.doi.org/10.1016/j.expneurol.2004.02.010]
[18]
Proescholdt, M.A.; Heiss, J.D.; Walbridge, S.; Mühlhauser, J.; Capogrossi, M.C.; Oldfield, E.H.; Merrill, M.J.; Oldfield, E.H.; Merrill, M.J. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J. Neuropathol. Exp. Neurol., 1999, 58(6), 613-627.
[http://dx.doi.org/10.1097/00005072-199906000-00006] [PMID: 10374752]
[19]
Vezzani, A.; Moneta, D.; Conti, M.; Richichi, C.; Ravizza, T.; De Luigi, A.; De Simoni, M.G.; Sperk, G.; Andell-Jonsson, S.; Lundkvist, J.; Iverfeldt, K.; Bartfai, T. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc. Natl. Acad. Sci. USA, 2000, 97(21), 11534-11539.
[http://dx.doi.org/10.1073/pnas.190206797] [PMID: 11016948]
[20]
Vezzani, A.; Moneta, D.; Richichi, C.; Aliprandi, M.; Burrows, S.J.; Ravizza, T.; Perego, C.; De Simoni, M.G. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia, 2002, 43(Suppl. 5), 30-35.
[http://dx.doi.org/10.1046/j.1528-1157.43.s.5.14.x] [PMID: 12121291]
[21]
Hanin, A.; Lambrecq, V.; Denis, J.A.; Imbert-Bismut, F.; Rucheton, B.; Lamari, F.; Bonnefont-Rousselot, D.; Demeret, S.; Navarro, V. Cerebrospinal fluid and blood biomarkers of status epilepticus. Epilepsia, 2020, 61(1), 6-18.
[http://dx.doi.org/10.1111/epi.16405] [PMID: 31828792]
[22]
Sutter, R.; Valença, M.; Tschudin-Sutter, S.; Rüegg, S.; Marsch, S. Procalcitonin and mortality in status epilepticus: an observational cohort study. Crit. Care, 2015, 19(1), 361.
[http://dx.doi.org/10.1186/s13054-015-1072-9] [PMID: 26450065]
[23]
Sculier, C.; Gaspard, N. New onset refractory status epilepticus (NORSE). Seizure, 2019, 68, 72-78.
[http://dx.doi.org/10.1016/j.seizure.2018.09.018] [PMID: 30482654]
[24]
Alkhachroum, A.; Der-Nigoghossian, C.A.; Rubinos, C.; Claassen, J. Markers in status epilepticus prognosis. J. Clin. Neurophysiol., 2020, 37(5), 422-428.
[http://dx.doi.org/10.1097/WNP.0000000000000761] [PMID: 32890064]
[25]
Specchio, N.; Pietrafusa, N. New‐onset refractory status epilepticus and febrile infection‐related epilepsy syndrome. Dev. Med. Child Neurol., 2020, 62(8), 897-905.
[http://dx.doi.org/10.1111/dmcn.14553] [PMID: 32372459]
[26]
Clarkson, B.D.S.; LaFrance-Corey, R.G.; Kahoud, R.J.; Farias-Moeller, R.; Payne, E.T.; Howe, C.L. Functional deficiency in endogenous interleukin‐1 receptor antagonist in patients with febrile infection‐related epilepsy syndrome. Ann. Neurol., 2019, 85(4), 526-537.
[http://dx.doi.org/10.1002/ana.25439] [PMID: 30779222]
[27]
Strohm, T.; Steriade, C.; Wu, G.; Hantus, S.; Rae-Grant, A.; Larvie, M. FDG-PET and MRI in the Evolution of New-Onset Refractory Status Epilepticus. AJNR Am. J. Neuroradiol., 2019, 40(2), 238-244.
[http://dx.doi.org/10.3174/ajnr.A5929] [PMID: 30679215]
[28]
Nardetto, L.; Zoccarato, M.; Santelli, L.; Tiberio, I.; Cecchin, D.; Giometto, B. 18F-FDG PET/MRI in cryptogenic new-onset refractory status epilepticus: a potential marker of disease location, activity and prognosis? J. Neurol. Sci., 2017, 381, 100-102.
[http://dx.doi.org/10.1016/j.jns.2017.08.021] [PMID: 28991656]
[29]
Bertoglio, D.; Verhaeghe, J.; Santermans, E.; Amhaoul, H.; Jonckers, E.; Wyffels, L.; Van Der Linden, A.; Hens, N.; Staelens, S.; Dedeurwaerdere, S. Non-invasive PET imaging of brain inflammation at disease onset predicts spontaneous recurrent seizures and reflects comorbidities. Brain Behav. Immun., 2017, 61, 69-79.
[http://dx.doi.org/10.1016/j.bbi.2016.12.015] [PMID: 28017648]
[30]
Szklener, S.; Korchut, A.; Godek, M.; Balicka-Adamik, L.; Bielecki, D.; Rejdak, R.; Rejdak, K. Systemic inflammatory response syndrome in the course of status epilepticus: 7-year, two-center observational study. Epilepsy Res., 2017, 137, 53-55.
[http://dx.doi.org/10.1016/j.eplepsyres.2017.09.003] [PMID: 28938136]
[31]
Gall, C.R.E.; Jumma, O.; Mohanraj, R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: Outcomes with early immunotherapy. Seizure, 2013, 22(3), 217-220.
[http://dx.doi.org/10.1016/j.seizure.2012.12.016] [PMID: 23333762]
[32]
Ramos, A.B.; Cruz, R.A.; Villemarette-Pittman, N.R.; Olejniczak, P.W.; Mader, E.C., Jr Dexamethasone as abortive treatment for Refractory seizures or status epilepticus in the inpatient setting. J. Investig. Med. High Impact Case Rep., 2019, 7.
[http://dx.doi.org/10.1177/2324709619848816] [PMID: 31104535]
[33]
Holtkamp, M. Pharmacotherapy for refractory and super-refractory status epilepticus in adults. Drugs, 2018, 78(3), 307-326.
[http://dx.doi.org/10.1007/s40265-017-0859-1] [PMID: 29368126]
[34]
Nelson, S.E.; Varelas, P.N. Status epilepticus, refractory status epilepticus, and super-refractory status epilepticus. Continuum (Minneap. Minn.), 2018, 24(6), 1683-1707.
[http://dx.doi.org/10.1212/CON.0000000000000668] [PMID: 30516601]
[35]
Westbrook, C.; Subramaniam, T.; Seagren, R.M.; Tarula, E.; Co, D.; Furstenberg-Knauff, M.; Wallace, A.; Hsu, D.; Payne, E. Febrile infection-related epilepsy syndrome treated successfully with anakinra in a 21-year-old woman. WMJ, 2019, 118(3), 135-139.
[PMID: 31682750]
[36]
Noe, F.M.; Polascheck, N.; Frigerio, F.; Bankstahl, M.; Ravizza, T.; Marchini, S.; Beltrame, L.; Banderó, C.R.; Löscher, W.; Vezzani, A. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol. Dis., 2013, 59, 183-193.
[http://dx.doi.org/10.1016/j.nbd.2013.07.015] [PMID: 23938763]
[37]
Jun, J.S.; Lee, S.T.; Kim, R.; Chu, K.; Lee, S.K. Tocilizumab treatment for new onset refractory status epilepticus. Ann. Neurol., 2018, 84(6), 940-945.
[http://dx.doi.org/10.1002/ana.25374] [PMID: 30408233]
[38]
Pitkänen, A.; Lukasiuk, K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol., 2011, 10(2), 173-186.
[http://dx.doi.org/10.1016/S1474-4422(10)70310-0] [PMID: 21256455]
[39]
Ambrogini, P.; Minelli, A.; Galati, C.; Betti, M.; Lattanzi, D.; Ciffolilli, S.; Piroddi, M.; Galli, F.; Cuppini, R. Post-seizure α-tocopherol treatment decreases neuroinflammation and neuronal degeneration induced by status epilepticus in rat hippocampus. Mol. Neurobiol., 2014, 50(1), 246-256.
[http://dx.doi.org/10.1007/s12035-014-8648-2] [PMID: 24488645]
[40]
Koh, S.; Dupuis, N.; Auvin, S. Ketogenic diet and Neuroinflammation. Epilepsy Res., 2020, 167106454
[http://dx.doi.org/10.1016/j.eplepsyres.2020.106454] [PMID: 32987244]
[41]
Kramer, U.; Chi, C.S.; Lin, K.L.; Specchio, N.; Sahin, M.; Olson, H.; Nabbout, R.; Kluger, G.; Lin, J.J.; van Baalen, A. Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome. Epilepsia, 2011, 52(11), 1956-1965.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03250.x] [PMID: 21883180]
[42]
Cruz, F.F.; Rocco, P.R.M.; Pelosi, P. Anti-inflammatory properties of anesthetic agents. Crit. Care, 2017, 21(1), 67.
[http://dx.doi.org/10.1186/s13054-017-1645-x] [PMID: 28320449]

Rights & Permissions Print Cite
Article Metrics
35
2
World Autism Awareness Day
© 2024 Bentham Science Publishers | Privacy Policy